William Blair analyst Matt Phipps initiated coverage of Evommune (EVMN) with an Outperform rating. The firm cites the potential of the company’s “first-in-class” MRGPRX2 inhibitor EVO756 in the treatment of chronic urticaria for the buy rating. Evommune has already established “strong” proof-of-concept data in both a human challenge study and a Phase II trial in patients with chronic inducible urticaria, which “de-risks” the ongoing Phase II trial in chronic spontaneous urticaria, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Promising Outlook for Evommune’s EVO756: Buy Rating Backed by Strong Data and Market Potential
- Evommune initiated with an Overweight at Morgan Stanley
- Promising Future for Evommune, Inc. in Inflammatory and Immunology Markets: Buy Rating Justified by Strong Pipeline and Experienced Leadership
- Opening Day: DNA test maker BillionToOne raises $314M in IPO